Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
| The first 150 words of the full text of this article appear below. |
EDITOR
Barbut and Meynard quote US guidance when recommending
vancomycin as first line treatment for antibiotic associated diarrhoea
in pregnancy.1
In the United Kingdom guidance issued by the medicines information centres and the National Teratology Information Service recommends metronidazole rather than oral vancomycin after a careful risk assessment of each drug.
Vancomycin is poorly absorbed from normal, intact gastrointestinal mucosa, but an inflammatory bowel process can result in increased absorption of the oral product. In patients with pseudomembranous colitis vancomycin may occasionally reach therapeutic concentrations in serum, which can theoretically damage a fetus's VIIIth cranial nerve.
In contrast, several epidemiological studies in women have shown no conclusive evidence that metronidazole causes an increased risk of malformations, stillbirths, or low birth weight.2-4 The accumulated data on more than 1500 births with prenatal exposure to metronidazole suggests no increase in congenital anomalies.2-4
In addition, a retrospective cohort study of nearly 1400 exposed
pregnancies